Theratechnologies

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 11

By Therapeutic Area

top 1

Oncology

1100%

R&D Momentum

12/100

Pipeline Velocity

0/100

Trial Completion Rate

67/100

Pipeline Concentration

100/100

Pipeline Freshness

44/100

Activity

Key Events

Jul 28, 2026TrialA Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab in a Real-World Setting: United States

Apr 18, 2022TrialThe Visceral Adiposity Measurement and Observation Study

Mar 4, 2021TrialTH1902 in Patients With Advanced Solid Tumors

Mar 6, 2018FDATROGARZO — TROGARZO

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Oncology

Patients With Advanced Solid Tumors

TH1902

Oncology

Patients With Advanced Solid Tumors

TH1902Phase 1

Regulatory

Regulatory Timeline

20101 event

FDANov 10

EGRIFTA WR — EGRIFTA WR

Application BLA022505 (BLA)

20181 event

FDAMar 6

TROGARZO — TROGARZO

Application BLA761065 (BLA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)